Sanofi and GSK Report Results of its COVID-19 Vaccine in a P-II Study Across All Adult Age Groups
Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021
Shots:
- The vaccine has achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a P-II study
- The results showed 95%-100% seroconversion following the second injection in all age groups (18-95yrs. old) & across all doses, with acceptable tolerability & no safety concerns. The high immune response following the single dose in patients with prior infection shows strong booster potential of the vaccine
- The companies are planning to start the P-III study in the coming weeks and are expecting the vaccine to be approved in Q4’21, following the positive P-III outcomes & regulatory reviews
Click here to read full press release/ article | Ref: Sanofi | Image: Medcity News